EUVIMEDEUVIMED entdecken
Open Access

Development of a Multiepitope Vaccine Against SARS-CoV-2: Immunoinformatics Study

Fatemeh Ghafouri iD, Reza Ahangari Cohan iD, Hilda Samimi iD, Ali Hosseini Rad S M iD, Mahmood Naderi iD, Farshid Noorbakhsh iD, Vahid Haghpanah iD

JMIR Bioinformatics and Biotechnology · 2022

DOI: 10.2196/36100 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JMIR Bioinformatics and Biotechnology, 2022. Verfasst von Fatemeh Ghafouri und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology Faculty of Life Sciences and Biotechnology Shahid Beheshti University Tehran Iran. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Since the first appearance of SARS-CoV-2 in China in December 2019, the world witnessed the emergence of the SARS-CoV-2 outbreak. Due to the high transmissibility rate of the virus, there is an urgent need to design and develop vaccines against SARS-CoV-2 to prevent more cases affected by the virus.

Objective

A computational approach is proposed for vaccine design against the SARS-CoV-2 spike (S) protein, as the key target for neutralizing antibodies, and envelope (E) protein, which contains a conserved sequence feature.

Methods

We used previously reported epitopes of S protein detected experimentally and further identified a collection of predicted B-cell and major histocompatibility (MHC) class II–restricted T-cell epitopes derived from E proteins with an identical match to SARS-CoV-2 E protein.

Results

The in silico design of our candidate vaccine against the S and E proteins of SARS-CoV-2 demonstrated a high affinity to MHC class II molecules and effective results in immune response simulations.

Conclusions

Based on the results of this study, the multiepitope vaccine designed against the S and E proteins of SARS-CoV-2 may be considered as a new, safe, and efficient approach to combatting the COVID-19 pandemic.

Schlagwörter

Stichwörter der Autor:innen

COVID-19COVID-19 vaccineSARS-CoV-2bioinformaticscomputational modelenvelope proteinimmunoinformaticsinformaticspandemicspike proteinvaccine design

Autor:innen und Institutionen

  • Department of Biotechnology Faculty of Life Sciences and Biotechnology Shahid Beheshti University Tehran Iran.
  • Department of Nanobiotechnology New Technologies Research Group Pasteur Institute of Iran Tehran Iran.
  • Endocrinology and Metabolism Research Center Endocrinology and Metabolism Clinical Sciences Institute Tehran University of Medical Sciences Tehran Iran.
  • Department of Microbiology and Immunology University of Otago Otago New Zealand.
  • Digestive Diseases Research Center Digestive Diseases Research Institute Tehran University of Medical Sciences Tehran Iran.
  • Department of Immunology School of Medicine Tehran University of Medical Sciences Tehran Iran.

ORCID-Profile: Fatemeh Ghafouri, Reza Ahangari Cohan, Hilda Samimi, Ali Hosseini Rad S M, Mahmood Naderi, Farshid Noorbakhsh, Vahid Haghpanah

Zitieren

APA

Ghafouri, F., Ahangari Cohan, R., Samimi, H., Hosseini Rad S M, A., Naderi, M., Noorbakhsh, F., & Haghpanah, V. (2022). Development of a Multiepitope Vaccine Against SARS-CoV-2: Immunoinformatics Study. JMIR Bioinformatics and Biotechnology. https://doi.org/10.2196/36100

Vancouver

Ghafouri F, Ahangari Cohan R, Samimi H, Hosseini Rad S M A, Naderi M, Noorbakhsh F, et al. Development of a Multiepitope Vaccine Against SARS-CoV-2: Immunoinformatics Study. JMIR Bioinformatics and Biotechnology. 2022. doi:10.2196/36100

BibTeX
@article{Ghafouri2022,
  author = {Ghafouri, Fatemeh and Ahangari Cohan, Reza and Samimi, Hilda and Hosseini Rad S M, Ali and Naderi, Mahmood and Noorbakhsh, Farshid and Haghpanah, Vahid},
  title = {Development of a Multiepitope Vaccine Against SARS-CoV-2: Immunoinformatics Study},
  journal = {JMIR Bioinformatics and Biotechnology},
  year = {2022},
  doi = {10.2196/36100}
}
Kostenlos starten →